Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT06010342 |
| Consolidated Lead Sponsor | Teligene US |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | RECRUITING |
| Registered Enrollment | 60 participants (ESTIMATED) |
| Registered Start Date | 2023-03-16 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Texas Oncology (Dallas) | Dallas, TX | Open Hospital Dossier -> |
| MD Anderson Cancer Center | Houston, TX | Open Hospital Dossier -> |
| Beijing Cancer Hospital | Beijing, China | Open Hospital Dossier -> |
| Chongqing University Cancer Hospital | Chongqing, China | Open Hospital Dossier -> |
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.